Submissions

Allergy & Anaphylaxis Australia (A&AA) is a charitable, non-profit organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals and their families to enjoy an optimal quality of life whilst minimising risk to their health and wellbeing. A&AA strives to raise awareness of allergy in the community and provides evidence-based information, resources and services to support children and adults living with allergic disease including food allergy.

Select a link below to access A&AA's submission.

Australian medicine labelling rules – Targeted consultation on priorities for future improvements to TGO 91 and TGO 92 - 7 September 2023

Do we need to update more medicine labelling rules in the short term to support medicine safety before we conduct a broader review? Yes, Allergy & Anaphylaxis Australia (A&AA) believes that an update is required in the short term to the ‘’Declaration of Substances’’, with respect to the food allergens that must be declared. It is vital that information...

PROPOSED DRAFT REVISION OF THE GENERAL STANDARD FOR THE LABELLING OF PRE-PACKAGED FOODS (CXS 1-1985) 4 September 2023

PROVISIONS RELEVANT TO ALLERGEN LABELLING (FOR ADOPTION AT STEP 5) Allergy & Anaphylaxis Australia (A&AA) does not support the proposed Draft Revision on the General Standard for the Labelling of Pre-Packaged Foods (CXS 1-1985): Provisions relevant to Allergen Labelling for adoption at Step 5. A&AA has several concerns that we needed to...

PROPOSED DRAFT GUIDELINES ON THE PROVISION OF FOOD INFORMATION FOR PRE-PACKAGED FOODS - 4 September 2023

OFFERED VIA E-COMMERCE (FOR ADOPTION AT STEP 5) Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Provision of Food Information for Prepackaged foods offered via E-Commerce for adoption at Step 5. A&AA has one point that we believe needs to be considered. The definition of ‘consumer’, referred to in the Purpose...

PROPOSED DRAFT GUIDELINES ON THE USE OF TECHNOLOGY TO PROVIDE FOOD INFORMATION - 4 September 2023 (2)

IN FOOD LABELLING (FOR ADOPTION AT STEP 5) Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Use of Technology to provide Food Information in Food Labelling for adoption at Step 5. However, we did have two issues that we feel need to be considered: The definition of consumer. In the Purpose statement...

P1028 – Infant formula | Special Medical Purpose Products for Infants (SMPPi) 7 July 2023

A&AA (Allergy & Anaphylaxis Australia) supports the proposal by FSANZ (Food Standards Australia New Zealand) to create a new category of infant formula that has been developed for a specific disease, disorder, or medical condition within Standard 2.9.1. A&AA supports the proposed sale restriction of a SMPPi (Special Medical Purpose Products for Infants)....

Ongoing PBS listing of Dupilumab for treatment of chronic severe atopic dermatitis - 15 May 2023

This submission from Allergy & Anaphylaxis Australia (A&AA) to the Pharmaceutical Benefits Advisory Committee concerns the ongoing Pharmaceutical Benefits Scheme listing of Dupilumab (Dupixent®) for the treatment of chronic severe atopic dermatitis in people aged 12 years and over. A&AA is grateful for the opportunity to forward a submission expressing...

Submission concerning Jorveza® for EoE change to current PBS listing - 23 Jan 2023

Submission from Allergy & Anaphylaxis Australia (A&AA): We welcome the opportunity to lodge our comments in support of the submission for Jorveza® (Budesonide) which is on the March 2023 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jorveza® was PBS listed in May 2022 specifically for the treatment of EoE. This application is for...

Submission on change to PBS listing Mepolizumab Injection - 15 Sep 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Change to PBS listing Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA supports the PBS listing of Mepolizumab so that people with chronic rhinosinusitis with nasal polyps can, together with their treating medical...

Submission concerning Codex Committee on Food Labelling | Response - 8 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Committee on Food Labelling | Electronic Working Group on Allergen Labelling. A&AA provides response on 1st Consultation Paper on the Codex eWG Allergen Labelling online-forum. Response form A&AA to Codex Committee on Food Labelling 8 July 2022195.71 KB ...

Submission concerning Codex Contact Point - 7 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Contact Point for Australia Secretariat A&AA appreciates the opportunity to provide feedback to the Codex Contact Point for Australia Secretariat on food information requirements for pre-packaged foods offered via e-commerce. Submission concerning Codex Contact Point - 7 July 2022224.86...

FSANZ submission: P1028 - Infant formula -14 June 2022

Allergy & Anaphylaxis Australia lodged a further submission with Food Standards Australia New Zealand (FSANZ) with regard to P1028 - Infant formula. A&AA supports the creation of a new category Special Medical Purpose Products for infants (SMPPi) within Standard 2.9.1, and supports the proposed labelling requirements for inner packages, preferably...

Submission concerning Dupixent for severe eczema - 16 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA):Dupixent for severe eczema. A&AA asks that you consider the changed lives of people with severe eczema who are now taking Dupixent in the July 2022 PBAC meeting. People are utilising the medication because there has been a huge need for a treatment that works without the need for immunosuppressive...

Submission concerning Review of the WA Food Act - 3 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Review of the WA Food Act. A&AA has no issue with the efficacy of the current provisions in the WA Food Act, noting that they appear in line with the Model Food Provisions. A&AA strongly urges the addition of provisions in the WA Food Act to address food allergy management throughout...

Submission concerning Food allergen content exemptions - 30 April 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Food allergen content exemptions cannot be considered because there is a huge food safety risk to consumers with food allergy. This will impact greatly on the health and wellbeing of people with food allergy and potentially add more of a challenge to an existing crisis such as Covid-19/natural disasters....

Submission concerning Proposal P1053: Food safety management tools - 6 April 2022

Allergy & Anaphylaxis Australia lodged a submission with Food Standards Australia New Zealand Food Standards Australia New Zealand (FSANZ) concerning Proposal P1053: Food safety management tools for the food service and closely related retail sectors. Submission from Allergy & Anaphylaxis Australia: Proposal P1053: Food safety management tools231.59...

Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022

Allergy & Anaphylaxis Australia lodged a submission with Codex Australia concerning the proposed Guidelines on the Use of Technology to Provide Food Information. A&AA Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022332.58 KB

PBAC Submission support for listing of Dupilumab (Dupixent®) on the PBS - 20 January 2022

Allergy & Anaphylaxis Australia lodged a submission with Pharmaceutical Benefits Advisory Committee (PBAC) supporting the Pharmaceutical Benefits Scheme (PBS) listing of Dupilumab (Dupixent®) for the treatment of severe atopic dermatitis (commonly known as eczema) in children aged 6 to 11 years. A&AA PBAC Submission for listing of Dupilumab (Dupixent®)...

Food Standards Australia New Zealand (FSANZ) submission: P1028 - Infant formula - 20 Oct 2021

Allergy & Anaphylaxis Australia lodged a submission with Food Standards Australia New Zealand (FSANZ) with regard to P1028 - Infant formula. With respect to the management of food allergy, A&AA has had access to the draft submissions of both the NAS and ASCIA and supports and endorses their submissions. A&AA FSANZ submission: P1028 - Infant formula...

Review of National Medicines Policy - Allergy and Anaphylaxis Australia submission - 8 Oct 2021

Allergy & Anaphylaxis Australia (A&AA) lodged a submission to the Review of National Medicines Policy. Included were submisions on: Terms of Reference 1: Evaluate the current NMP objectives and determine whether these should be modified or additional objectives included. This includes consideration of the proposed Principles to be included...

PBAC Budesonide (Jorveza®) submission for use in EoE (Eosinophilic Oesoghagitis) - 22 Sep 2021

Allergy & Anaphylaxis Australia lodged comments in support of the application for Pharmaceutical Benefits Scheme (PBS) listing of JORVEZA® for both induction of remission and maintenance of remission in adult patients with Eosinophilic Oesophagitis (EoE). A&AA PBAC Budesonide (Jorveza®) submission for use in EoE (Eosinophilic Oesoghagitis) - 22 Sep 2021175.93...